A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers

Cephalalgia

Volumn 33, Issue 10, 2013, Pages 853-860

  Varnäs, Katarina ^a   Jučaite, Aurelija ^a,b   McCarthy, Dennis J ^c   Stenkrona, Per ^a   Nord, Magdalena ^a   Halldin, Christer ^a   Farde, Lars ^a,c   Kanes, Stephen ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

5 HT1B receptors; Brain imaging; NCT01085123; PET; serotonin; zolmitriptan

Indexed keywords

CARBON 11; SEROTONIN 1B RECEPTOR; ZOLMITRIPTAN;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; MALE; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY;

5-HT1B RECEPTORS; BRAIN IMAGING; PET; SEROTONIN; ZOLMITRIPTAN;

ADULT; BENZOPYRANS; BRAIN; CARBON RADIOISOTOPES; HUMANS; MALE; MORPHOLINES; OXAZOLIDINONES; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TRYPTAMINES; YOUNG ADULT;

EID: 84879380170     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413476372     Document Type: Article

References (35)

1. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002 ; 59: 1084-1088 (Pubitemid 34755820)
2. May A. A review of diagnostic and functional imaging in headache. J Headache Pain. 2006 ; 7: 174-184 (Pubitemid 46206330)
3. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995 ; 1: 658-660
4. Afridi SK, Giffin NJ, Kaube H, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol. 2005 ; 62: 1270-1275 (Pubitemid 41168356)
5. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001 ; 98: 4687-4692 (Pubitemid 32295037)
6. Cao Y, Welch KM, Aurora S, et al. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol. 1999 ; 56: 548-554 (Pubitemid 29218149)
7. Castro ME, Pascual J, Romón T, et al. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology. 1997 ; 36: 535-542 (Pubitemid 27273212)
8. Hamel E. Serotonin and migraine: Biology and clinical implications. Cephalalgia. 2007 ; 27: 1293-1300
9. Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 ; 17: 4-14
10. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat. Cephalalgia. 1997 ; 17: 153-158 (Pubitemid 27257339)
11. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin 5HT1B/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine?. Pain. 1996 ; 67: 355-359 (Pubitemid 26375351)
12. de Almeida RM, Nikulina EM, Faccidomo S, et al. Zolmitriptan - a 5-HT1B/D agonist, alcohol, and aggression in mice. Psychopharmacology (Berl). 2001 ; 157: 131-141 (Pubitemid 32802124)
13. Proietti-Cecchini A, Afra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: Demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia. 1997 ; 17: 849-854
14. Bergström M, Yates R, Wall A, et al. Blood-brain barrier penetration of zolmitriptan - modelling of positron emission tomography data. J Pharmacokinet Pharmacodyn. 2006 ; 33: 75-91
15. Lindhe Ö, Almqvist P, Kågedal M, et al. Autoradiographic mapping of 5-HT1B/1D binding sites in the rhesus monkey brain using [carbonyl-11C]zolmitriptan. Int J Mol Imaging 2011; 2011: Article ID 694179, 6 pages, doi: 10. 1155/2011/694179.
16. Varnäs K, Hall H, Bonaventure P, et al. Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR 125743. Brain Res. 2001 ; 915: 47-57 (Pubitemid 32907491)
17. Pierson ME, Andersson J, Nyberg S, et al. AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. NeuroImage. 2008 ; 41: 1075-1085
18. Bergström M, Boethius J, Eriksson L, et al. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr. 1981 ; 5: 136-141 (Pubitemid 11161171)
19. Varrone A, Sjöholm N, Eriksson L, et al. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009 ; 36: 1639-1650
20. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996 ; 4: 153-158
21. Varnäs K, Nyberg S, Halldin C, et al. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011 ; 31: 113-123
22. Cselényi Z, Olsson H, Halldin C, et al. A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635. NeuroImage. 2006 ; 32: 1690-1708 (Pubitemid 44332262)
23. Andrée B, Thorberg SO, Halldin C, et al. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl). 1999 ; 144: 303-305 (Pubitemid 29307285)
24. Bantick RA, Rabiner EA, Hirani E, et al. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology. 2004 ; 29: 847-859 (Pubitemid 38528764)
25. Melichar JK, Hume SP, Williams TM, et al. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther. 2005 ; 312: 309-315 (Pubitemid 40096483)
26. Kling MA, Carson RE, Borg L, et al. Opioid receptor imaging with positron emission tomography and [18F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000 ; 295: 1070-1076
27. Fujita M, Woods SW, Verhoeff NP, et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol. 1999 ; 368: 161-172 (Pubitemid 29117137)
28. Lingford-Hughes A, Wilson SJ, Feeney A, et al. A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. Psychopharmacology (Berl). 2005 ; 180: 789-791 (Pubitemid 41317875)
29. Grimwood S, Hartig PR. Target site occupancy: Emerging generalizations from clinical and preclinical studies. Pharmacol Ther. 2009 ; 122: 281-301
30. Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997 ; 121: 157-164 (Pubitemid 27192699)
31. Maier DL, Sobotka-Briner C, Ding M, et al. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: In vitro characterization and in vivo receptor occupancy. J Pharmacol Exp Ther. 2009 ; 330: 342-351
32. Finnema SJ, Varrone A, Hwang TJ, et al. Confirmation of fenfluramine effect on 5-HT1B receptor binding of [11C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab. 2012 ; 32: 685-695
33. Schuh-Hofer S, Richter M, Geworski L, et al. Increased serotonin transporter availability in the brainstem of migraineurs. J Neurol. 2007 ; 254: 789-796 (Pubitemid 47012461)
34. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: An indication of cortical potentiation and low serotonergic neurotransmission?. Neurology. 1996 ; 46: 1404-1409 (Pubitemid 26159305)
35. Sakai Y, Dobson C, Diksic M, et al. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology. 2008 ; 70: 431-439